Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - 3SBio Inc.'s success with a biosimilar of Amgen Inc.'s erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government
Advertisement

Related Content

3SBio Discontinues NuLeusin; Sinovac To Benefit From Government Vaccine Supply Plan: China Earnings Roundup (Part 3)
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
With Government Support, China Medical City Looks To Separate Itself From The Pack
With Government Support, China Medical City Looks To Separate Itself From The Pack
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
Is China A Black Swan For Big Pharma? (Part 2 of 2)
3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)
Lilly Asian Ventures Looking For Chinese Companies To Invest In
Advertisement
UsernamePublicRestriction

Register

SC078823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel